Respiratory syncytial virus pre-fusion glycoprotein f mrna
As of the edition of 20 October 2026, Respiratory syncytial virus pre-fusion glycoprotein f mrna is a vaccine component: marketed, first approved in 2024 (US); US protection ends in 2036.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Vaccine component
- Brand name
- mresvia
- First approved
- 31 May 2024 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- ModernaTX
US protection
US protection ends in 2036.
The reference-product exclusivity ends in 2036. The application that gives this date is held by ModernaTX.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.